MULTIPLE MYELOMA

A retrospective analysis shows strong outcomes with CAR T-cell therapy in real-world patients with multiple myeloma, Doris K. Hansen, MD, explains.

The phase 3 trial showed benefit with talquetamab/daratumumab with or without pomalidomide as early as the second line in myeloma.

In vivo anti-BCMA CAR T infusion shows favorable efficacy and safety with some patients beyond 9 months free of progression.

During a live event, Sikander Ailawadhi, MD, and participants discussed sequencing and bridging therapy selection for patients with early relapsed multiple myeloma who are candidates for CAR T-cell therapy.

During a live event, Syed Abbas Ali, MBBS, and participants discussed current referral practices for second-line CAR T-cell therapy in multiple myeloma.

SUCCESSOR-2 shows oral mezigdomide plus carfilzomib/dexamethasone extends PFS to 18 months in high-risk relapsed myeloma.

Belantamab plus VRd in newly diagnosed myeloma yields response rates over 85% with dose schedules to manage ocular toxicity.

In an in-depth interview, Omar Nadeem, MD, explores the promising findings from 20 patients with smoldering myeloma treated with cilta-cel.

Omar Nadeem, MD, discusses results of the CAR-PRISM trial in smoldering myeloma.

A phase 1 trial investigating autologous KMCAR T cells has been initiated in patients with relapsed/refractory multiple myeloma.

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Andrzej Jakubowiak, MD, PhD, explains promising results for KRd maintenance and the potential of modifying the posttransplant maintenance paradigm in multiple myeloma.

During a live event, Caitlin Costello, MD, discussed the tools used to evaluate risk status for smoldering myeloma.

Andrzej Jakubowiak, MD, PhD, discusses how the ATLAS trial intensified, then deescalated posttransplant maintenance in newly diagnosed multiple myeloma.

During a live event, Patrick Hagen, MD, evaluated the safety profile of the MajesTEC-3 regimen and considered the impact of early use of teclistamab in multiple myeloma.

CLOVER-WaM data meet FDA-requested threshold; confirmatory trial planned for fourth quarter 2026.

The BCMA-CD3 bispecific antibody outperformed daratumumab plus pomalidomide and dexamethasone in double-class exposed patients.

During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.

Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient groups.

As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions.

The target date for the FDA's decision on isatuximab via on-body injector is now July 23, 2026.

Clinical trials show subcutaneous isatuximab is preferred by patients, enabling faster dosing, home treatment, and paving the way for future self-administration.

On-body injector isatuximab enables at-home myeloma treatment, cutting infusion visits, easing time and financial strain, and expanding access for rural patients.

During a live event, Binod Dhakal, MD, discussed the rationale for choosing therapy given before CAR T-cell infusion in multiple myeloma.

On-body isatuximab injection matches IV results in relapsed multiple myeloma, with similar safety, drug levels, and better convenience.